(FWIW)...
BOSTON--(BUSINESS WIRE)--Jan. 15, 2003-- GlycoGenesys, Inc. (NASDAQ:GLGS - News) today announced that it was cited in the February cover story of MIT's Technology Review, entitled "10 Emerging Technologies That Will Change The World." The magazine's editors identified 10 emerging technologies that they predict will have "a tremendous influence in the near future." One of the 10 emerging technologies picked by the magazine's editorial staff was Glycomics, or the study of the biology of sugars, the platform on which GlycoGenesys has developed its anti-cancer compound, GCS-100.
The section on Glycomics outlines important research contributions made by James Paulson, a researcher at the Scripps Research Institute in La Jolla, CA, and head of the Consortium for Functional Glycomics, a group comprised of approximately 40 academics from a number of disciplines that has a five-year $34 million grant from the National Institutes of Health.
The section also notes important contributions being made by biotech companies in Glycomics, such as Amgen's improvements to its existing protein-based drug, erythropoietin, and the development of Glycomic drugs in human clinical trials by companies such as GlycoGenesys and Oxford Glycoscience for ailments ranging from colorectal cancer to Gaucher's disease.
GlycoGenesys, Inc.
GlycoGenesys is a biopharmaceutical company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. In February 2002, the Company initiated a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California. In the area of agriculture, GlycoGenesys continues to seek strategic alternatives for Elexa- 4® Plant Defense Booster. Further information is available on GlycoGenesys' web site: www.glycogenesys.com. |
